<DOC>
	<DOCNO>NCT01738646</DOCNO>
	<brief_summary>It show bevacizumab significant anti-tumor activity patient recurrent glioblastoma multiforme . Vorinostat modest anti-tumor activity malignant glioma enhance action chemotherapy anti-angiogenics . Patients treated combination bevacizumab vorinostat .</brief_summary>
	<brief_title>Ph II SAHA Bevacizumab Recurrent Malignant Glioma Patients</brief_title>
	<detailed_description>There effective therapy patient recurrent glioblastoma multiforme ( GBM ) hence patient remain major unmet need oncology . The investigator recently demonstrate bevacizumab ( BV ) , humanize monoclonal antibody vascular endothelial growth factor , significant anti-tumor activity among recurrent glioblastoma multiforme patient . Vorinostat modest anti-tumor activity malignant glioma potentiate action chemotherapy anti-angiogenics . The current study design evaluate anti-tumor activity vorinostat combine BV among recurrent glioblastoma multiforme patient .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Age &gt; 18 year . An interval least 4 week prior surgical resection one week stereotactic biopsy . An interval least 12 week end prior radiotherapy unless new area enhancement consistent recurrent tumor outside radiation field , biopsyproven tumor progression An interval least 4 week prior chemotherapy [ 6 week nitrosoureas , 1 week daily administer chemotherapy ( metronomic dosing ) ] investigational agent unless patient recover anticipated toxicity associate therapy . Eastern Cooperative Oncology Group ( ECOG ) 01 . Hematocrit ≥ 29 % , hemoglobin ≥ 9 , absolute neutrophil ≥1,500 cells/microliter , platelet ≥ 100,000 cells/microliters . Serum creatinine , serum glutamic oxaloacetic transaminase ( SGOT ) bilirubin &lt; 1.5 time upper limit normal . Signed informed consent approve Institutional Review Board prior patient entry . No evidence hemorrhage baseline MRI CT scan stable grade 1 . If sexually active , patient take contraceptive measure duration treatment . Medically acceptable contraceptive include : ( 1 ) surgical sterilization ( tubal ligation , hysterectomy , vasectomy ) , ( 2 ) approve hormonal contraceptive ( birth control pill , patch , implant injection ) , ( 3 ) barrier method ( condom diaphragm ) use spermicide , ( 4 ) intrauterine device ( IUD ) . Diseasespecific exclusion More 2 prior episode disease progression Prior therapy histone deacetylase inhibitor ; valproic acid permit patient previously treat valproic acid must valproic acid least 30 day prior initiation study medication Prior bevacizumab therapy Comedication may interfere study result ; e.g . immunosuppressive agent corticosteroid Active infection require intravenous antibiotic Severe hepatic insufficiency , active viral hepatitis HIV infection Requires therapeutic anticoagulation warfarin General medical exclusion Subjects meet follow criterion ineligible study entry : Inability comply study and/or followup procedure Bevacizumabspecific exclusion Inadequately control hypertension ( define systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) Any prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Grade II great congestive heart failure ( see Appendix E ) History myocardial infarction unstable angina within 6 month prior study enrollment History stroke transient ischemic attack within 6 month prior study enrollment Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) Symptomatic peripheral vascular disease Evidence bleed diathesis coagulopathy Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study enrollment anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior study enrollment History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study enrollment Serious , nonhealing wound , ulcer , bone fracture Proteinuria screening demonstrate either : Urine protein : creatinine ( UPC ) ratio &gt; = 1.0 screening OR Urine dipstick proteinuria ≥ 2+ ( patient discover ≥2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate ≤ 1g protein 24 hour eligible ) . Known hypersensitivity component bevacizumab Pregnant ( positive pregnancy test ) lactating . Refuse use effective mean contraception ( men woman ) subject childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>vorinostat</keyword>
	<keyword>SAHA</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>AVASTIN</keyword>
	<keyword>malignant glioma</keyword>
	<keyword>GBM</keyword>
	<keyword>glioblastoma multiforme</keyword>
	<keyword>brain tumor</keyword>
</DOC>